Bladder cancer cocktail trial: which immunotherapy combo works best?
NCT ID NCT03869190
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combination shrank tumors or slowed cancer growth. Patients received atezolizumab (an immunotherapy) plus one or two other drugs, and the trial was designed to drop ineffective combos and add new ones as data emerged.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Athens Medical Center
Athens, 151 25, Greece
-
Attiko Hospital University of Athens
Athens, 12462, Greece
-
Centre Francois Baclesse
Caen, 14076, France
-
Centre Leon Berard
Lyon, 69008, France
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, LA Coruna, 15706, Spain
-
Hospital Clinic i Provincial
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital General Universitario Gregorio Mara
Madrid, 28009, Spain
-
Hospital Univ 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz.
Madrid, 28040, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Institut Catala d Oncologia Hospitalet
Barcelona, 08908, Spain
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut régional du Cancer Montpellier
Montpellier, 34298, France
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Memorial Sloan-Kettering Cancer Center
Commack, New York, 11725, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40241, United States
-
Royal Marsden NHS Foundation Trust
Sutton, SM2 5PT, United Kingdom
-
START Madrid. Centro Integral Oncologico Clara Campal
Madrid, 28050, Spain
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 120-749, South Korea
-
Stanford Cancer Center
Stanford, California, 94305-5820, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
UCLA Department of Medicine
Los Angeles, California, 90024, United States
-
UCSF Comprehensive Cancer Ctr
San Francisco, California, 94115, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44016, United States
-
University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536, United States
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (an immunotherapy drug) combined with other drugs like enfortumab vedotin, niraparib, or tiragolumab
What this could lead to
If successful, this could identify better combination treatments for advanced bladder cancer that are more effective than current options.
What could go wrong
This is an early-phase study (Phase 1/2) with a small number of participants. Many combinations may not work better than standard care, and side effects from the drug cocktails could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.